Abstract
B lymphocytes make several contributions to immune regulation including production of antibodies with regulatory properties, release of immune suppressive cytokines, and expression of death-inducing ligands. A role for Fas ligand (FasL)-expressing “killer” B cells in regulating T helper (TH) cell survival and chronic inflammation has been demonstrated in animal models of schistosome worm and other infections, asthma, autoimmune arthritis, and type 1 diabetes. FasL+ B cells were also capable of inducing immune tolerance in a male-to-female transplantation model. Interestingly, populations of B cells found in the spleen and lungs of naïve mice constitutively expresses FasL and have potent killer function against TH cells that is antigen-specific and FasL-dependent. Epstein-Barr virus-transformed human B cells constitutively express FasL and package it into exosomes that co-express MHC Class II molecules and have killer function against antigen-specific TH cells. FasL+ exosomes with markers of B-cell lineage are abundant in the spleen of naïve mice. Killer B cells therefore represent a novel target for immune modulation in many disease settings. Our laboratory has published methods of characterizing FasL+ B cells and inducing their proliferation in vitro. This updated chapter will describe methods of identifying and expanding killer B cells from mice, detecting FasL expression in B cells, extracting FasL+ exosomes from spleen and culture supernatants, and performing functional killing assays against antigen-specific TH cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Roths JB, Murphy ED, Eicher EM (1984) A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 159(1):1–20
Sobel ES, Kakkanaiah VN, Cohen PL, Eisenberg RA (1993) Correction of gld autoimmunity by co-infusion of normal bone marrow suggests that gld is a mutation of the Fas ligand gene. Int Immunol 5(10):1275–1278
Lynch DH, Watson ML, Alderson MR, Baum PR, Miller RE, Tough T, Gibson M, Davis-Smith T, Smith CA, Hunter K et al (1994) The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1(2):131–136
Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76(6):969–976
Hahne M, Peitsch MC, IrmLer M, Schroter M, Lowin B, Rousseau M, Bron C, Renno T, French L, Tschopp J (1995) Characterization of the non-functional Fas ligand of gld mice. Int Immunol 7(9):1381–1386
Adachi M, Watanabe-Fukunaga R, Nagata S (1993) Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci U S A 90(5):1756–1760
Wu J, Zhou T, He J, Mountz JD (1993) Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 178(2):461–468
Nagata S, Suda T (1995) Fas and Fas ligand: lpr and gld mutations. Immunol Today 16(1):39–43
Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81(6):935–946
Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268(5215):1347–1349
Bleesing JJ (2005) Sorting out the causes of ALPS. J Pediatr 147(5):571–574. https://doi.org/10.1016/j.jpeds.2005.09.025
Infante AJ, Britton HA, DeNapoli T, Middelton LA, Lenardo MJ, Jackson CE, Wang J, Fleisher T, Straus SE, Puck JM (1998) The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J Pediatr 133(5):629–633
Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler-Stevenson M, Strober W (1992) A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest 90(2):334–341. https://doi.org/10.1172/JCI115867
Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, Neven B, Schaffner C, Ducrot N, Arkwright PD, Bader-Meunier B, Barbot J, Blanche S, Casanova JL, Debre M, Ferster A, Fieschi C, Florkin B, Galambrun C, Hermine O, Lambotte O, Solary E, Thomas C, Le Deist F, Picard C, Fischer A, Rieux-Laucat F (2009) FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood 113(13):3027–3030. https://doi.org/10.1182/blood-2008-09-179630
Stroncek DF, Carter LB, Procter JL, Dale JK, Straus SE (2001) RBC autoantibodies in autoimmune lymphoproliferative syndrome. Transfusion 41(1):18–23
Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD (1996) Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 98(5):1107–1113
Kojima T, Horiuchi T, Nishizaka H, Sawabe T, Higuchi M, Harashima SI, Yoshizawa S, Tsukamoto H, Nagasawa K, Niho Y (2000) Analysis of fas ligand gene mutation in patients with systemic lupus erythematosus. Arthritis Rheum 43(1):135–139
Atkinson EA, Bleackley RC (1995) Mechanisms of lysis by cytotoxic T cells. Crit Rev Immunol 15(3–4):359–384
Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S (1996) Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 157(7):2909–2915
Hahne M, Renno T, Schroeter M, IrmLer M, French L, Bornard T, MacDonald HR, Tschopp J (1996) Activated B cells express functional Fas ligand. Eur J Immunol 26(3):721–724
Lundy SK (2009) Killer B lymphocytes: the evidence and the potential. Inflammation Research 58(7):345–357. https://doi.org/10.1007/s00011-009-0014-x
Lundy SK, Lerman SP, Boros DL (2001) Soluble egg antigen-stimulated T helper lymphocyte apoptosis and evidence for cell death mediated by FasL(+) T and B cells during murine Schistosoma mansoni infection. Infect Immun 69(1):271–280
Lundy SK, Boros DL (2002) Fas ligand-expressing B-1a lymphocytes mediate CD4(+)-T-cell apoptosis during schistosomal infection: induction by interleukin 4 (IL-4) and IL-10. Infect Immun 70(2):812–819
Lundy SK, Berlin AA, Martens TF, Lukacs NW (2005) Deficiency of regulatory B cells increases allergic airway inflammation. Inflammation Research 54(12):514–521. https://doi.org/10.1007/s00011-005-1387-0
Lundy SK, Fox DA (2009) Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis. Arthritis Res Ther 11(4):R128. https://doi.org/10.1186/ar2795
Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL (2001) Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 167(2):1081–1089
Montandon R, Korniotis S, Layseca-Espinosa E, Gras C, Megret J, Ezine S, Dy M, Zavala F (2013) Innate pro-B-cell progenitors protect against type 1 diabetes by regulating autoimmune effector T cells. Proc Natl Acad Sci U S A 110(24):E2199–E2208. https://doi.org/10.1073/pnas.1222446110
Bonardelle D, Benihoud K, Kiger N, Bobe P (2005) B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice. J Leukoc Biol 78(5):1052–1059. https://doi.org/10.1189/jlb.0904536
Zuniga E, Motran CC, Montes CL, Yagita H, Gruppi A (2002) Trypanosoma cruzi infection selectively renders parasite-specific IgG+ B lymphocytes susceptible to Fas/Fas ligand-mediated fratricide. J Immunol 168(8):3965–3973
Minagawa R, Okano S, Tomita Y, Kishihara K, Yamada H, Nomoto K, Shimada M, Maehara Y, Sugimachi K, Yoshikai Y, Nomoto K (2004) The critical role of Fas-Fas ligand interaction in donor-specific transfusion-induced tolerance to H-Y antigen. Transplantation 78(6):799–806. https://doi.org/10.1097/01.tp.0000129799.96439.6f
Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270(5239):1189–1192
Mohan RR, Liang Q, Kim WJ, Helena MC, Baerveldt F, Wilson SE (1997) Apoptosis in the cornea: further characterization of Fas/Fas ligand system. Exp Eye Res 65(4):575–589
Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA (1997) CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 99(3):396–402
Jorgensen A, Wiencke AK, la Cour M, Kaestel CG, Madsen HO, Hamann S, Lui GM, Scherfig E, Prause JU, Svejgaard A, Odum N, Nissen MH, Ropke C (1998) Human retinal pigment epithelial cell-induced apoptosis in activated T cells. Invest Ophthalmol Vis Sci 39(9):1590–1599
Sapi E, Brown WD, Aschkenazi S, Lim C, Munoz A, Kacinski BM, Rutherford T, Mor G (2002) Regulation of Fas ligand expression by estrogen in normal ovary. J Soc Gynecol Investig 9(4):243–250
Li H, Ren J, Dhabuwala CB, Shichi H (1997) Immunotolerance induced by intratesticular antigen priming: expression of TGF-beta, Fas and Fas ligand. Ocul Immunol Inflamm 5(2):75–84
Uckan D, Steele A, Cherry WBY, Chamizo W, Koutsonikolis A, Gilbert-Barness E, Good RA (1997) Trophoblasts express Fas ligand: a proposed mechanism for immune privilege in placenta and maternal invasion. Mol Hum Reprod 3(8):655–662. https://doi.org/10.1093/molehr/3.8.655
Kauma SW, Huff TF, Hayes N, Nilkaeo A (1999) Placental Fas ligand expression is a mechanism for maternal immune tolerance to the fetus. J Clin Endocrinol Metab 84(6):2188–2194
Silvestris F, Tucci M, Cafforio P, Dammacco F (2001) Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood 97(5):1155–1164
Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil R (1998) Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 91(11):4273–4281
Lettau M, Paulsen M, Kabelitz D, Janssen O (2009) FasL expression and reverse signalling. Results Probl Cell Differ 49:49–61. https://doi.org/10.1007/400_2008_21
Kavurma MM, Khachigian LM (2003) Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ 10(1):36–44
Chow WA, Fang JJ, Yee JK (2000) The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. J Immunol 164(7):3512–3518
Sayed D, He M, Hong C, Gao S, Rane S, Yang Z, Abdellatif M (2010) MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 285(26):20281–20290. https://doi.org/10.1074/jbc.M110.109207
Li JH, Rosen D, Ronen D, Behrens CK, Krammer PH, Clark WR, Berke G (1998) The regulation of CD95 ligand expression and function in CTL. J Immunol 161(8):3943–3949
Zuccato E, Blott EJ, Holt O, Sigismund S, Shaw M, Bossi G, Griffiths GM (2007) Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation. J Cell Sci 120(Pt 1):191–199. https://doi.org/10.1242/jcs.03315
Mincheff M, Loukinov D, Zoubak S, Hammett M, Meryman H (1998) Fas and Fas ligand expression on human peripheral blood leukocytes. Vox Sang 74(2):113–121
Martinez-Lorenzo MJ, Anel A, Gamen S, Monle NI, Lasierra P, Larrad L, Pineiro A, Alava MA, Naval J (1999) Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol 163(3):1274–1281
Jodo S, Xiao S, Hohlbaum A, Strehlow D, Marshak-Rothstein A, Ju ST (2001) Apoptosis-inducing membrane vesicles. A novel agent with unique properties. J Biol Chem 276(43):39938–39944. https://doi.org/10.1074/jbc.M107005200
Sabapatha A, Gercel-Taylor C, Taylor DD (2006) Specific isolation of placenta-derived exosomes from the circulation of pregnant women and their immunoregulatory consequences. Am J Reprod Immunol 56(5–6):345–355. https://doi.org/10.1111/j.1600-0897.2006.00435.x
McKechnie NM, King BC, Fletcher E, Braun G (2006) Fas-ligand is stored in secretory lysosomes of ocular barrier epithelia and released with microvesicles. Exp Eye Res 83(2):304–314. https://doi.org/10.1016/j.exer.2005.11.028
Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S (1997) Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 3(7):738–743
Takeuchi T, Ueki T, Nishimatsu H, Kajiwara T, Ishida T, Jishage K, Ueda O, Suzuki H, Li B, Moriyama N, Kitamura T (1999) Accelerated rejection of Fas ligand-expressing heart grafts. J Immunol 162(1):518–522
Gregory MS, Repp AC, Holhbaum AM, Saff RR, Marshak-Rothstein A, Ksander BR (2002) Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J Immunol 169(5):2727–2735
Mariani SM, Matiba B, BaumLer C, Krammer PH (1995) Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 25(8):2303–2307
Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM (1999) The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9(24):1441–1447
Sano Y, Yamada J, Ishino Y, Adachi W, Kawasaki S, Suzuki T, Kinoshita S, Okuyama T, Azuma N (2002) Non-cleavable mutant Fas ligand transfection of donor cornea abrogates ocular immune privilege. Exp Eye Res 75(4):475–483
Lundy SK, Klinker MW, Fox DA (2015) Killer B lymphocytes and their fas ligand positive exosomes as inducers of immune tolerance. Front Immunol 6:122. https://doi.org/10.3389/fimmu.2015.00122
Klinker MW, Reed TJ, Fox DA, Lundy SK (2013) Interleukin-5 supports the expansion of Fas ligand-expressing killer B cells that induce antigen-specific apoptosis of CD4(+) T cells and secrete Interleukin-10. PLoS One 8(8):e70131. https://doi.org/10.1371/journal.pone.0070131
Martin F, Kearney JF (2001) B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 13(2):195–201
Yang Y, Tung JW, Ghosn EE, Herzenberg LA, Herzenberg LA (2007) Division and differentiation of natural antibody-producing cells in mouse spleen. Proc Natl Acad Sci U S A 104(11):4542–4546. https://doi.org/10.1073/pnas.0700001104
Kantor AB, Stall AM, Adams S, Watanabe K, Herzenberg LA (1995) De novo development and self-replenishment of B cells. Int Immunol 7(1):55–68
Yoshimoto M, Montecino-Rodriguez E, Ferkowicz MJ, Porayette P, Shelley WC, Conway SJ, Dorshkind K, Yoder MC (2011) Embryonic day 9 yolk sac and intra-embryonic hemogenic endothelium independently generate a B-1 and marginal zone progenitor lacking B-2 potential. Proc Natl Acad Sci U S A 108(4):1468–1473. https://doi.org/10.1073/pnas.1015841108
Klinker MW, Lundy SK (2012) Multiple mechanisms of immune suppression by B lymphocytes. Mol Med 18:123–137. https://doi.org/10.2119/molmed.2011.00333
Morita Y, Gupta R, Seidl KM, McDonagh KT, Fox DA (2005) Cytokine production by dendritic cells genetically engineered to express IL-4: induction of Th2 responses and differential regulation of IL-12 and IL-23 synthesis. J Gene Med 7(7):869–877. https://doi.org/10.1002/jgm.730
Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM (1997) CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100(11):2757–2765. https://doi.org/10.1172/JCI119822
Taitano SH, van der Vlugt L, Shea MM, Yang J, Lukacs NW, Lundy SK (2018) Differential influence on regulatory B cells by TH2 cytokines affects protection in allergic airway disease. J Immunol 201(7):1865–1874. https://doi.org/10.4049/jimmunol.1800206
Klinker MW, Lizzio V, Reed TJ, Fox DA, Lundy SK (2014) Human B cell-derived Lymphoblastoid cell lines constitutively produce Fas ligand and secrete MHCII(+)FasL(+) killer Exosomes. Front Immunol 5:144. https://doi.org/10.3389/fimmu.2014.00144
Herzenberg LA, Tung J, Moore WA, Herzenberg LA, Parks DR (2006) Interpreting flow cytometry data: a guide for the perplexed. Nat Immunol 7(7):681–685. https://doi.org/10.1038/ni0706-681
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Lundy, S.K., Taitano, S.H., van der Vlugt, L.E.P.M. (2021). Characterization and Activation of Fas Ligand-Producing Mouse B Cells and Their Killer Exosomes. In: Mion, F., Tonon, S. (eds) Regulatory B Cells. Methods in Molecular Biology, vol 2270. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1237-8_9
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1237-8_9
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1236-1
Online ISBN: 978-1-0716-1237-8
eBook Packages: Springer Protocols